Abbott Laboratories raised its full-year 2026 adjusted diluted EPS guidance to a range of $5.45 to $5.60, up from the prior $5.38 to $5.58, following fiscal second-quarter results that beat estimates. Sales in the diagnostics segment, which includes the recently acquired Exact Sciences colorectal cancer screening test Cologuard, rose 42% to $3.09 billion, surpassing the $3.02 billion estimate and emerging as the quarter's strongest performer. The company reaffirmed its full-year comparable sales growth guidance of 6.5% to 7.5%, while worldwide nutrition sales fell 3.1% on a reported basis, though they improved sequentially by $127 million from the first quarter. William Blair reiterated an Outperform rating, noting that the diagnostics results should improve sentiment around the Exact Sciences acquisition and that growth in medical devices helps offset concerns about hospital procedure volumes.
Abbott LaboratoriesStrong demand for cancer diagnostics (Cologuard) and medical devices drove Q2 beat and raised guidance.